3SBio files for Chinese approval of anemia drug
High-dose EPIAO is designed for the rapid restoration of hemoglobin to normal levels among cancer patients. According to the company, the 36,000 IU dosage is comparable to the
The US Food and Drug Administration (FDA) has approved an expanded indication for Eli Lilly and Company’s Jaypirca (pirtobrutinib) as a first-line treatment for adults with previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) who do not have a 17p deletion.